Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
29 Aug 2017 Adolescent and Young Adult Cancer Survivors Are Less Likely to Have HPV-Vaccination than Peers Cancer in Special Situations - Epidemiology/Etiology/Cancer Prevention
23 Aug 2017 Concept Paper on Development and Lifecycle of Personalised Medicines and Companion Diagnostics Personalised medicine - Bioethics, legal and economic issues
22 Aug 2017 FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL Haematologic malignancies - Anticancer agents & Biologic therapy
21 Aug 2017 FDA Expands Ibrutinib Indications to Chronic GVHD Cancer in Special Situations - Haematologic malignancies - Anticancer agents & Biologic therapy
18 Aug 2017 FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
18 Aug 2017 FDA Approves Liposome-Encapsulated Combination of Daunorubicin-Cytarabine for Adults with Some Types of Poor Prognosis AML Haematologic malignancies - Anticancer agents & Biologic therapy
17 Aug 2017 Liquid Biopsy Screening for Nasopharyngeal Carcinoma Epidemiology/Etiology/Cancer Prevention - Head and neck cancers
16 Aug 2017 EU Commission Launches Public Consultation on Health and Care in the Digital Single Market Bioethics, legal and economic issues
15 Aug 2017 FDA Grants Regular Approval to Enasidenib for the Treatment of Relapsed or Refractory AML Personalised medicine - Haematologic malignancies - Anticancer agents & Biologic therapy
14 Aug 2017 The EU needs a more coherent research funding landscape Bioethics, legal and economic issues
11 Aug 2017 FDA Grants Nivolumab Accelerated Approval for MSI-H or dMMR Colorectal Cancer Cancer in Special Situations - Gastrointestinal cancers - Cancer Immunology and Immunotherapy
10 Aug 2017 FDA Accepts Applications for Nivolumab Four Week Dosing Schedule Across All Approved Indications Cancer Immunology and Immunotherapy
08 Aug 2017 EMA Recommends Refusal of the Marketing Authorisation for Etirinotecan Pegol Breast cancer - Anticancer agents & Biologic therapy
08 Aug 2017 Response Evaluation and Biomarker Development in Onco-Immunology
07 Aug 2017 EMA Adopts a New Indication for Obinutuzumab Haematologic malignancies - Anticancer agents & Biologic therapy